OCUGEN, INC. Form 8-K (Dec. 30, 2021)

Summary

Current report on Form 8-K of Ocugen, Inc., dated December 30, 2021, filed under Items 8.01 and 9.01. Item 8.01 states that on December 30, 2021 the company issued a press release announcing that its partner, Bharat Biotech, posted results on the pre-print server medRXiv from a Phase 2/3 trial in India of the candidate vaccine COVAXIN (BBV152) in children aged 2 to 18 years. The release describes the results as demonstrating a robust neutralizing antibody response and favorable safety profile. The press release is Exhibit 99.1, and the signature block shows /s/ Shankar Musunuri.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“OCUGEN, INC. Form 8-K (Dec. 30, 2021).” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-ocgn-8-k-filed2021-12-30-0001104659-21-154719-86800da293/, SHA-256 4e1fc282e6992457f2c2805b31729b4c48d8ff955866fe1872c6926b01ad0166.

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15
(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event
Reported): December 30, 2021

OCUGEN, INC.

(Exact Name of Registrant as Specified in
its Charter)

Delaware | 001-36751 | 04-3522315
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number)

263 Great Valley Parkway

Malvern , Pennsylvania 19355

( 484 ) 328-4701

(Addresses, including zip code, and telephone
numbers, including area code, of principal executive offices)

N/A

(Former Name or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8–K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):

¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting
material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
¨ | Pre–commencement
communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
¨ | Pre–commencement
communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))

Securities registered pursuant to Section
12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.01 par value per share | OCGN | The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging
growth company ¨

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨

Item 8.01 Other Events.

On December 30, 2021, Ocugen, Inc. issued a press release
announcing that its partner, Bharat Biotech, posted results from a Phase 2/3 trial conducted in
India of candidate vaccine, COVAXIN™ (BBV152), in children, aged 2 – 18 years, demonstrating a robust neutralizing antibody
response and favorable safety profile on the pre-print server, medRXiv. A copy of this press
release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial
Statements and Exhibits.

The following exhibits are being filed herewith:

(d) Exhibits

Exhibit No. | Document
99.1 | Press Release of Ocugen, Inc. dated December 30, 2021.
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 30, 2021

OCUGEN, INC.
By: | /s/ Shankar Musunuri
Name: Shankar Musunuri
Title: Chief Executive Officer and Chairman

3

File and source

File: SEC_OCGN_8-K_filed2021-12-30_0001104659-21-154719.htm
Size: 27,182 bytes
SHA-256: 4e1fc282e6992457f2c2805b31729b4c48d8ff955866fe1872c6926b01ad0166
Our copy: SEC_OCGN_8-K_filed2021-12-30_0001104659-21-154719.htm
Original: www.sec.gov